Lung Cancer Tumor Board: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal is Cure

Welcome and Introductions

Defining Resectability for Stage I-III NSCLC in the Era of Chemoimmunotherapy and Chemoradiotherapy Treatment Paradigms

Coordination of the Lung Cancer Care Team to Integrate Immunotherapy in Resectable NSCLC

Building on Current Immunotherapeutic Standards for Combined Modality Therapy in Unresectable Stage III NSCLC

A Multidisciplinary Approach to Managing Immune-Related Adverse Events